4D Molecular Therapeutics, Inc. (FDMT) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, 4D Molecular Therapeutics reported revenue of $85.2M, up 230194.6% from $37,000 the year before. Net income was -$140.1M (a -164.4% net margin), or -$2.42 per diluted share. Operating margin was -187.2%. Operating activities generated -$109.1M of cash, leaving -$109.6M of free cash flow. At fiscal year end, 4D Molecular Therapeutics held $566.7M in total assets against $61.0M in total liabilities, including $60.2M of cash and equivalents.
Open the full interactive 4D Molecular Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
4D Molecular Therapeutics Key Stats
| Share Price | $12.36 |
|---|---|
| Market Cap | $868.6M |
| 52-Week Range | $7.19 – $16.76 |
| Shares Outstanding | 70.3 million (basic, 2026 Q2) |
4D Molecular Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $13.6M | $18.0M | $3.1M | $20.7M | $37,000 | $85.2M |
| Operating Income | -$56.7M | -$71.3M | -$110.0M | -$112.9M | -$187.8M | -$159.5M |
| Pre-Tax Income | -$56.7M | -$71.3M | -$107.5M | -$100.8M | -$160.9M | -$140.1M |
| Income Tax | — | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$56.7M | -$71.3M | -$107.5M | -$100.8M | -$160.9M | -$140.1M |
| Diluted EPS | -$8.82 | -$2.57 | -$3.32 | -$2.58 | -$2.98 | -$2.42 |
4D Molecular Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $90,000 | $85.1M | $3.0M | $3.8M |
| Net Income | -$56.9M | $19.4M | -$68.8M | -$72.9M |
| Diluted EPS | -$1.01 | $0.33 | -$1.01 | -$1.04 |
4D Molecular Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $276.7M | $153.0M | $52.4M | $249.1M | $149.3M | $60.2M |
| Current Assets | $282.7M | $256.3M | $220.5M | $296.6M | $434.9M | $413.1M |
| Total Assets | $288.3M | $353.5M | $261.8M | $339.9M | $560.4M | $566.7M |
| Current Liabilities | $16.7M | $16.3M | $15.7M | $19.0M | $29.1M | $44.0M |
| Total Liabilities | $31.9M | $34.4M | $30.5M | $32.1M | $49.8M | $61.0M |
| Shareholders' Equity | $256.4M | $319.1M | $231.3M | $307.8M | $510.6M | $505.7M |
4D Molecular Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$50.9M | -$69.1M | -$86.7M | -$75.8M | -$134.6M | -$109.1M |
| Cash From Investing | -$1.0M | -$172.7M | -$17.1M | $115.7M | -$302.4M | -$93.0M |
| Cash From Financing | $279.0M | $118.1M | $3.1M | $156.8M | $337.2M | $113.0M |
| Free Cash Flow | -$51.9M | -$78.2M | -$98.2M | -$78.6M | -$138.4M | -$109.6M |
Figures from 4D Molecular Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full 4D Molecular Therapeutics financials page for every line item.
4D Molecular Therapeutics Company Profile
| Ticker | FDMT |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Emeryville, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001650648 |
Frequently Asked Questions
What was 4D Molecular Therapeutics' revenue in fiscal 2025?
4D Molecular Therapeutics (FDMT) reported revenue of $85.2M for fiscal 2025.
What is 4D Molecular Therapeutics' annual revenue history?
4D Molecular Therapeutics' annual revenue by fiscal year: 2020: $13.6M; 2021: $18.0M; 2022: $3.1M; 2023: $20.7M; 2024: $37,000; 2025: $85.2M.
What was 4D Molecular Therapeutics' net income in fiscal 2025?
4D Molecular Therapeutics reported net income of -$140.1M for fiscal 2025.
What was 4D Molecular Therapeutics' earnings per share (EPS) in fiscal 2025?
4D Molecular Therapeutics' diluted EPS was -$2.42 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did 4D Molecular Therapeutics generate in fiscal 2025?
4D Molecular Therapeutics generated -$109.6M of free cash flow in fiscal 2025.
What was 4D Molecular Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), 4D Molecular Therapeutics reported revenue of $3.8M.
How many shares of 4D Molecular Therapeutics are outstanding?
4D Molecular Therapeutics reported a weighted average of 70.3 million basic shares outstanding in 2026 Q2.
What is 4D Molecular Therapeutics' market cap?
Based on its latest closing price, 4D Molecular Therapeutics (FDMT) has a market capitalization of about $868.6M.
When does 4D Molecular Therapeutics' fiscal year end?
4D Molecular Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is 4D Molecular Therapeutics headquartered?
4D Molecular Therapeutics lists its business address in Emeryville, California in its SEC filings.
4D Molecular Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →